ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

Accuray Reports Third Quarter Fiscal 2021 Financial Results https://finance.yahoo.com/news/accuray-reports-third-quarter-fiscal-200700151.html Third Quarter Fiscal 2021 Summary • Net revenue of $102.6 million including $24.9 million of system revenue in China • Gross orders of $87.4 million, an increase of 16 percent from the second quarter of fiscal 2021 • GAAP operating income of $4.4 million, GAAP net loss of $0.4 million, and Adjusted EBITDA of $8.7 million • Received Shonin regulatory approval in Japan for ClearRT™ Helical kVCT Imaging for the Radixact® System ...

https://m.youtube.com/watch?v=QQrDZVn5ZpA&feature=youtu.be

https://share-your-photo.com/9760783eb3

Werden wir nicht kommen

Unter 4€ sollte bitte vermieden werden

Danke für deine Infos!

Trainingsstützpunkt eröffnet 💪

https://share-your-photo.com/9995fc0fe3

https://m.youtube.com/watch?v=wR6_cTHprO4&feature=emb_title&ab_channel=AccurayIncorporated

Yes Baby - Newsflow passt

https://www.accuray.com/head-neck-imrt-tomohelical/

Im Forum von Stereotaxis gefunden. Accuray findet seinen Platz im Podcast (bzw dem Text): https://7investing.com/articles/robotics-in-healthcare-with-brian-gahsman/ Robotics in Healthcare with Brian Gahsman

Der Kurs könnte ja bald interessant werden 🤔

Advanced Product Mix Gives Accuray A Shot At Success In U.S. And Overseas https://seekingalpha.com/article/4415328-advanced-product-mix-gives-accuray-shot-success-in-us-overseas Summary • Accuray has a portfolio of radiotherapy products that are generating revenues of ~$380m per annum. • The company is one of only a few competitors in an exciting growth space and area of unmet need, although its competitors are far bigger and better resourced. • Its sales have been flat for 2-3 years and share price stagnant for longer, but the stock has been on a bull run over the past 6 months. • Accuray is pursuing a first-to-market opportunity in China where there is a shortage of radiotherapy treatments, albeit progress has been subject to delays. • Its fundamentals - i.e. P/S ratio of 1.3x - point to the company being undervalued and its products capable of challenging for a growing market share, in my view.

https://www.hackensackmeridianhealth.org/patient-perspectives/living-pain-free-after-trigeminal-neuralgia/

https://www.cyberknifemiami.com/earls-story-treating-kidney-cancer-at-cyberknife-miami-saving-both-kidneys/